Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Oct 15;102(8):1534–1539. doi: 10.1172/JCI4059

The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.

S B Liggett 1, L E Wagoner 1, L L Craft 1, R W Hornung 1, B D Hoit 1, T C McIntosh 1, R A Walsh 1
PMCID: PMC509003  PMID: 9788966

Abstract

The beta2-adrenergic receptor (beta2AR), an important modulator of cardiac inotropy and chronotropy, has significant genetic heterogeneity in the population. Because dysfunctional betaARs play a role in the pathogenesis of the failing ventricle, we tested the hypothesis that beta2AR polymorphisms alter the outcome of congestive heart failure. 259 patients with NYHA functional class II-IV heart failure due to ischemic or dilated cardiomyopathy were genotyped and prospectively followed, with the endpoint defined as death or cardiac transplantation. The allele frequencies between this group and those of 212 healthy controls also were compared and did not differ between the groups. However, those with the Ile164 polymorphism displayed a striking difference in survival with a relative risk of death or cardiac transplant of 4.81 (P < 0.001) compared with those with the wild-type Thr at this position. Age, race, gender, functional class, etiology, ejection fraction, and medication use did not differ between these individuals and those with the wild-type beta2AR, and thus the beta2AR genotype at position 164 was the only clear distinguishing feature between the two groups. The 1-yr survival for Ile164 patients was 42% compared with 76% for patients harboring wild-type beta2AR. In contrast, polymorphisms at amino acid positions 16 (Arg or Gly) or 27 (Gln or Glu), which also alter receptor phenotype, did not appear to have an influence on the course of heart failure. Taken together with cell-based and transgenic mouse results, this study establishes a paradigm whereby genetic variants of key signaling elements can have pathophysiologic consequences within the context of a disease. Furthermore, patients with the Ile164 polymorphism and heart failure may be candidates for earlier aggressive intervention or cardiac transplantation.

Full Text

The Full Text of this article is available as a PDF (181.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aass H., Skomedal T., Osnes J. B. Increase of cyclic AMP in subcellular fractions of rat heart muscle after beta-adrenergic stimulation: prenalterol and isoprenaline caused different distribution of bound cyclic AMP. J Mol Cell Cardiol. 1988 Sep;20(9):847–860. doi: 10.1016/s0022-2828(88)80009-9. [DOI] [PubMed] [Google Scholar]
  2. Akhter S. A., Skaer C. A., Kypson A. P., McDonald P. H., Peppel K. C., Glower D. D., Lefkowitz R. J., Koch W. J. Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12100–12105. doi: 10.1073/pnas.94.22.12100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  4. Bristow M. R., Ginsburg R., Umans V., Fowler M., Minobe W., Rasmussen R., Zera P., Menlove R., Shah P., Jamieson S. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep;59(3):297–309. doi: 10.1161/01.res.59.3.297. [DOI] [PubMed] [Google Scholar]
  5. Bristow M. R., Hershberger R. E., Port J. D., Minobe W., Rasmussen R. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar;35(3):295–303. [PubMed] [Google Scholar]
  6. Dewar J. C., Wilkinson J., Wheatley A., Thomas N. S., Doull I., Morton N., Lio P., Harvey J. F., Liggett S. B., Holgate S. T. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol. 1997 Aug;100(2):261–265. doi: 10.1016/s0091-6749(97)70234-3. [DOI] [PubMed] [Google Scholar]
  7. Edelberg J. M., Aird W. C., Rosenberg R. D. Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest. 1998 Jan 15;101(2):337–343. doi: 10.1172/JCI1330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gilbert E. M., Olsen S. L., Renlund D. G., Bristow M. R. beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993 Mar 25;71(9):23C–29C. doi: 10.1016/0002-9149(93)90083-o. [DOI] [PubMed] [Google Scholar]
  9. Green S. A., Cole G., Jacinto M., Innis M., Liggett S. B. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993 Nov 5;268(31):23116–23121. [PubMed] [Google Scholar]
  10. Green S. A., Turki J., Bejarano P., Hall I. P., Liggett S. B. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 1995 Jul;13(1):25–33. doi: 10.1165/ajrcmb.13.1.7598936. [DOI] [PubMed] [Google Scholar]
  11. Green S. A., Turki J., Innis M., Liggett S. B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994 Aug 16;33(32):9414–9419. doi: 10.1021/bi00198a006. [DOI] [PubMed] [Google Scholar]
  12. Hall I. P., Wheatley A., Wilding P., Liggett S. B. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet. 1995 May 13;345(8959):1213–1214. doi: 10.1016/s0140-6736(95)91994-5. [DOI] [PubMed] [Google Scholar]
  13. Hall R. A., Premont R. T., Chow C. W., Blitzer J. T., Pitcher J. A., Claing A., Stoffel R. H., Barak L. S., Shenolikar S., Weinman E. J. The beta2-adrenergic receptor interacts with the Na+/H+-exchanger regulatory factor to control Na+/H+ exchange. Nature. 1998 Apr 9;392(6676):626–630. doi: 10.1038/33458. [DOI] [PubMed] [Google Scholar]
  14. Ho K. K., Anderson K. M., Kannel W. B., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993 Jul;88(1):107–115. doi: 10.1161/01.cir.88.1.107. [DOI] [PubMed] [Google Scholar]
  15. Hohl C. M., Li Q. A. Compartmentation of cAMP in adult canine ventricular myocytes. Relation to single-cell free Ca2+ transients. Circ Res. 1991 Nov;69(5):1369–1379. doi: 10.1161/01.res.69.5.1369. [DOI] [PubMed] [Google Scholar]
  16. Insel P. A. Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors--evolving concepts and clinical implications. N Engl J Med. 1996 Feb 29;334(9):580–585. doi: 10.1056/NEJM199602293340907. [DOI] [PubMed] [Google Scholar]
  17. Kannel W. B., Belanger A. J. Epidemiology of heart failure. Am Heart J. 1991 Mar;121(3 Pt 1):951–957. doi: 10.1016/0002-8703(91)90225-7. [DOI] [PubMed] [Google Scholar]
  18. Martinez F. D., Graves P. E., Baldini M., Solomon S., Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997 Dec 15;100(12):3184–3188. doi: 10.1172/JCI119874. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Milano C. A., Allen L. F., Rockman H. A., Dolber P. C., McMinn T. R., Chien K. R., Johnson T. D., Bond R. A., Lefkowitz R. J. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 1994 Apr 22;264(5158):582–586. doi: 10.1126/science.8160017. [DOI] [PubMed] [Google Scholar]
  20. Motulsky H. J., Cunningham E. M., DeBlasi A., Insel P. A. Desensitization and redistribution of beta-adrenergic receptors on human mononuclear leukocytes. Am J Physiol. 1986 May;250(5 Pt 1):E583–E590. doi: 10.1152/ajpendo.1986.250.5.E583. [DOI] [PubMed] [Google Scholar]
  21. Nikiforov T. T., Rendle R. B., Goelet P., Rogers Y. H., Kotewicz M. L., Anderson S., Trainor G. L., Knapp M. R. Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms. Nucleic Acids Res. 1994 Oct 11;22(20):4167–4175. doi: 10.1093/nar/22.20.4167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Packer M., Carver J. R., Rodeheffer R. J., Ivanhoe R. J., DiBianco R., Zeldis S. M., Hendrix G. H., Bommer W. J., Elkayam U., Kukin M. L. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991 Nov 21;325(21):1468–1475. doi: 10.1056/NEJM199111213252103. [DOI] [PubMed] [Google Scholar]
  23. Parmley W. W. Cost-effective management of heart failure. Clin Cardiol. 1996 Mar;19(3):240–242. doi: 10.1002/clc.4960190319. [DOI] [PubMed] [Google Scholar]
  24. Reihsaus E., Innis M., MacIntyre N., Liggett S. B. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993 Mar;8(3):334–339. doi: 10.1165/ajrcmb/8.3.334. [DOI] [PubMed] [Google Scholar]
  25. Rockman H. A., Koch W. J., Milano C. A., Lefkowitz R. J. Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice. J Mol Med (Berl) 1996 Sep;74(9):489–495. doi: 10.1007/BF00204974. [DOI] [PubMed] [Google Scholar]
  26. Tan S., Hall I. P., Dewar J., Dow E., Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997 Oct 4;350(9083):995–999. doi: 10.1016/S0140-6736(97)03211-X. [DOI] [PubMed] [Google Scholar]
  27. Turki J., Lorenz J. N., Green S. A., Donnelly E. T., Jacinto M., Liggett S. B. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10483–10488. doi: 10.1073/pnas.93.19.10483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Turki J., Pak J., Green S. A., Martin R. J., Liggett S. B. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest. 1995 Apr;95(4):1635–1641. doi: 10.1172/JCI117838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Waagstein F., Caidahl K., Wallentin I., Bergh C. H., Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation. 1989 Sep;80(3):551–563. doi: 10.1161/01.cir.80.3.551. [DOI] [PubMed] [Google Scholar]
  30. Wagoner L. E., Walsh R. A. The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol. 1996 May;11(3):237–244. doi: 10.1097/00001573-199605000-00003. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES